{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:29:52Z","timestamp":1787131792081,"version":"build-2736575974"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) exhibits multiple therapeutic properties, but its use in advanced cancer patients raises concerns about potential drug\u2013drug interactions (DDIs) due to polypharmacy. This study aims to look for evidence of DDIs between concomitant medications and CBD oil in a randomized placebo-controlled trial of CBD oil for symptom control (MedCan-1 parent study).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Surrogate measures were used to identify possible drug interactions: (1) the maximum mL of oil self-selected by patients in CBD or placebo groups in relation to opioids, specific drug groups, or individual agents; (2) the occurrence of any new or worse adverse effect in relation to the study arm and the concomitant medication classes\/medications of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The dose of CBD self-selected by participants was not related to opioid use or medications, including benzodiazepines and antipsychotics. The likelihood of developing an adverse effect while on study or when taking specific medications was not increased by CBD. Participants on paracetamol tolerated a higher dose of CBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Concerns regarding the development of clinically significant drug interactions when taking CBD in the context of anti-cancer and other concomitant medications at least in the short term may be unfounded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2024.0041","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:05:41Z","timestamp":1731557141000},"page":"138-146","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Interactions in People on Cannabidiol: Is There Cause for Concern?"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7287-1103","authenticated-orcid":false,"given":"Georgia","family":"Downs","sequence":"first","affiliation":[{"name":"Mater Research Institute, University of Queensland, Raymond Terrace, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ristan","family":"Greer","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Raymond Terrace, Brisbane, Australia."},{"name":"Torus Research, Brisbane, Queensland, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Moses","sequence":"additional","affiliation":[{"name":"Mater Misericordiae Ltd, Raymond Terrace, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9695-9109","authenticated-orcid":false,"given":"Taylan","family":"Gurgenci","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Raymond Terrace, Brisbane, Australia."},{"name":"Mater Misericordiae Ltd, Raymond Terrace, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Good","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Raymond Terrace, Brisbane, Australia."},{"name":"Mater Misericordiae Ltd, Raymond Terrace, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hardy","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Raymond Terrace, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00724"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072348"},{"key":"e_1_3_5_4_2","volume-title":"Therapeutic Goods Administration Medicinal Cannabis - Guidance Documents","author":"Australian Government Department of Health","year":"2017","unstructured":"Australian Government Department of Health. Therapeutic Goods Administration Medicinal Cannabis - Guidance Documents. Therapeutic Goods Administration (TGA); 2017."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1071\/CH21006"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.02.017"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.05.018"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13064"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.098541"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6010003"},{"issue":"2","key":"e_1_3_5_12_2","first-page":"213","article-title":"Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers","volume":"26","author":"Zuardi AW","year":"1993","unstructured":"Zuardi AW, , Guimar\u00e3es F, , Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res, 1993; 26(2):213\u2013217.","journal-title":"Braz J Med Biol Res"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300340"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.07.027"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.004"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06504-8"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13852"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13060"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01632"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riac073"},{"key":"e_1_3_5_21_2","volume-title":"GP Pain Help [Mobile Application Software] (Version 1.7","year":"2018","unstructured":"GP Pain Help [Mobile Application Software] (Version 1.7. CPCRE: Queensland, Australia; 2018."},{"key":"e_1_3_5_22_2","volume-title":"Australian Medicines Handbook. Online database","year":"2023","unstructured":"Australian Medicines Handbook. Online database. Amhonline.amh.net.au. July 2023."},{"key":"e_1_3_5_23_2","unstructured":"National Cancer Institute. Common terminology criteria for adverse effects v4.0 (CTCAE) (2009). Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2019.0540"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070989"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010307"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13351"},{"key":"e_1_3_5_28_2","volume-title":"Subscription Database","author":"Youscript","year":"2023","unstructured":"Youscript. Subscription Database. Youscript.net; 2023."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3256"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2142114"},{"issue":"3","key":"e_1_3_5_31_2","first-page":"23","article-title":"Cannabis drug interactions","volume":"42","author":"Harnett J","year":"2023","unstructured":"Harnett J, , Chan J, , Hunter J. Cannabis drug interactions. Aust Pharm, 2023; 42(3):23\u201338.","journal-title":"Aust Pharm"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0020"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04541-6"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2024.0041","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2024.0041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2024.0041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:22:09Z","timestamp":1787131329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2024.0041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1089\/can.2024.0041"],"URL":"https:\/\/doi.org\/10.1089\/can.2024.0041","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}